 |
|
|
| |
PRELIMINARY EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN PATIENTS WITH HCV GENOTYPE 1-6 INFECTION AND COMPENSATED CIRRHOSIS: THE EXPEDITION-8 STUDY
|
| |
| |
Reported by Jules Levin
Presented at the AASLD: The Liver Meeting® San Francisco, CA
13 November 2018
Robert S Brown Jr1, Christophe Hezode2, Stanley Wang3, Maria Buti4, Wan-Long Chuang5, Humberto Aguilar6, Gabor Horvath7, Barbara Rosado Carrion8, Federico Rodriguez-Perez9, Eric Cohen3, Yiran B Hu3, Gretja Schnell3, Chih-Wei Lin3*, Lino Rodrigues3, Roger Trinh3, Federico J Mensa3, Franco Felizarta10
1Weill Cornell Medical College, Center for Liver Disease and Transplantation, New York, NY, USA; 2. Department of Hepatology, Hopital Henri Mondor, Université Paris-Est, Paris, France; 3. AbbVie Inc., North Chicago, Illinois, United States; 4. Vall d'Hebron University Hospital and CiBERHED del Instituto Carlos III, Barcelona, Spain; 5. Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 6. Louisiana Research Center, Shreveport, LA, USA; 7. Hepatology Center of Buda, Budapest, Hungary; 8. Director of GHGCPR Research Institute, Puerto Rico; 9. GHWC and Gastroenterology Section, San Juan, Puerto Rico; 10. Private Practice, Bakersfield, California, USA *Employee of AbbVie during the study; current employee of Amgen.
|
| |
|
|
|
|
|
